NCT01016912View on ClinicalTrials.gov

Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha-2b and Ribavirin) in Japanese Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

September 30, 2010

Study Completion Date

September 30, 2010

Conditions
Hepatitis C Infection
Interventions
DRUG

BMS-790052

Tablets, Oral, 10 mg, daily, 24-48 weeks

DRUG

BMS-790052

Tablets, Oral, 60 mg, daily, 24-48 weeks

DRUG

Placebo

Tablets, Oral, 0 mg, daily, 48 weeks

DRUG

Peginterferon alfa-2b

Syringe, Subcutaneous, 180µg, weekly, 24-48 weeks

DRUG

Ribavirin

Capsules, Oral, 600 to 1000 mg based on weight, daily, 24-48 weeks

Trial Locations (6)

2138587

Local Institution, Kawasaki-Shi

3500495

Local Institution, Iruma-Gun

5650871

Local Institution, Suita-Shi

734-0037

Local Institution, Hiroshima

060-0033

Local Institution, Sapporo

105-0001

Local Institution, Minato-Ku

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY